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Abstract:
Abstract 
Objectives 
An aging UK population and multi-morbidity means patients are 
receiving an increasing number of medicines. This can lead to greater 
risk of unintended side effects. The aim of this study was to increase 
understanding of how people identify and manage side effects from their 
medicines. 
Design 
A qualitative interview study with patients who had experienced side 
effects, recruited from community pharmacies. 
Methods 
This study examined patients’ experiences of side effects and the impact 
of these effects on their daily life. Fifteen participants were interviewed - 
ten females and five males, with ages that ranged between 25 and 80 
years, using different types and numbers of medicines. Results 
Thematic analysis revealed six themes; side effect experience, 
identification, adherence, information use, coping and body awareness. 
Participants described a wide range of physical and psychological 
symptoms which had both explicit and implicit impact on their lives. A 
system of identification based on constructed cognitive processes was 
common across participants. A variety of strategies were used by 
participants to cope with their side effects which included information 
seeking, social support seeking and non-adherent behaviours. 
Conclusions 
Psychological factors, such as medication beliefs, symptom 
interpretation and body awareness, contribute to cognitive and 
behavioural processes used to identify and manage side effects. 
These processes can have significant impacts on an individual’s 
decisions about adherence.   
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Abstract 
Objectives 
An aging UK population and multi-morbidity means patients are receiving an increasing 
number of medicines. This can lead to greater risk of unintended side effects. The aim of 
this study was to increase understanding of how people identify and manage side effects 
from their medicines.  
Design 
A qualitative interview study with patients who had experienced side effects, recruited 
from community pharmacies.  
Methods 
This study examined patients’ experiences of side effects and the impact of these effects on 
their daily life. Fifteen participants were interviewed - ten females and five males, with 
ages that ranged between 25 and 80 years, using different types and numbers of medicines. 
Results 
Thematic analysis revealed six themes; side effect experience, identification, 
adherence, information use, coping and body awareness. Participants described a 
wide range of physical and psychological symptoms which had both explicit and 
implicit impact on their lives. A system of identification based on constructed 
cognitive processes was common across participants. A variety of strategies were 
used by participants to cope with their side effects which included information 
seeking, social support seeking and non-adherent behaviours. 
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Conclusions 
Psychological factors, such as medication beliefs, symptom interpretation and 
body awareness, contribute to cognitive and behavioural processes used to 
identify and manage side effects. These processes can have significant impacts on 
an individual’s decisions about adherence.   
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‘You feel like you haven’t got any control’: A qualitative study of side effects from 
medicines. 
Introduction 
Medicines are frequently the most cost effective and least invasive medical 
treatments available to individuals. However, a progressively aging population 
and accompanying multi-morbidity mean there are an increasing number of 
medicines being prescribed for people by health professionals today in the UK.
1
 
All medicines have the potential to cause side effects, but the increase in multiple 
medicine use has contributed to an increase in the risk of unintended harmful 
effects or adverse drug reactions (ADRs) in the ambulatory care setting. The 
definition of an ADR used by the World Health Organisation (WHO) is “a 
response to a drug that is noxious and unintended and occurs at doses normally 
used in man for the prophylaxis, diagnosis or therapy of disease, or for 
modification of physiological function.” 2 An adverse reaction is therefore a 
damaging and unintended response to a medicine, where a causal relationship is 
suspected. This differs from an adverse event which describes the harm that 
happens while a patient is taking a drug, regardless of whether the drug is 
suspected to be the cause. Adverse responses to medicine are sometimes referred 
to as side effects (SE) and frequently the terms ADRs and SE are used 
interchangeably in patient information and other contexts. Side effects from 
medicines can have considerable impact on peoples’ lives. This impact can be 
significant and extend into many aspects of daily life with physical, economic, 
social and/or psychological effects.
3,4,5,6,7,8 
Side effects have been identified as the 
fifth most common cause of death in developed countries.
9
 Research conducted 
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into the frequency of side effects has varied across studies with prevalence rates 
that range from 0.15% - 30%.
10
 Risk factors have been identified such as complex 
medical history, low income and age which are associated with increased rates of 
side effects. Research has suggested that older patients and those with low 
economic status are more likely to experience severe side effects.
11 
These risk 
factors add to the frequent morbidity and mortality associated with side 
effects.
12,13
 Side effects have a significant impact on public health, placing 
significant economic burden on stretched healthcare services.
14,15
 The financial 
burden of side effects on the National Health Service (NHS) can be considerable 
resulting in increased costs in caring for patients, delays in treatment as well as 
prolonged hospital stays with one in seven hospital inpatients experiencing severe 
side effects.
14
 Even if a severe side effect episode is successfully resolved patients 
can experience numerous long term complications.
15
 Such complications can be 
multidimensional in nature with b th physical and psychological elements.
4
 
Health researchers and healthcare organisations worldwide have realised that side 
effects are a public health issue which requires strategic attention and effective 
interventions. However difficulties exist in identifying people who have 
experienced side effects resulting in recruitment problems for research studies. 
Therefore, only limited qualitative research has been conducted amongst this 
population to date. 
16,17, 18,19
 This study sought to add to the literature, providing 
greater understanding of this topic by focusing on particular perspectives; forming 
a rich, contextualised picture of individuals’ experiences of side effects through 
in-depth interviews. Specifically the study aim was to investigate how people 
identified and managed side effects from their medicines.  
Methods 
Participants 
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A purposive sample of participants who had experienced side effects from their 
medicines were recruited. All participants were pharmacy customers 18 years or 
over, resident in the UK and proficient in English. The participants were recruited 
through a survey distributed in community pharmacies to people using 
prescription or purchased medicines which sought to determine use of information 
sources to learn about medicine side effects. Ethical approval was obtained from 
the NHS Research Ethics Service via the Proportionate Review Sub-committee of 
the NRES Committee North East - Newcastle & North Tyneside 1 (REC ref 
14/NE/1053). 
Procedure 
The survey instrument included an invitation to take part in an interview for any 
respondent with a recent side effect experience. Potential participants indicated 
their willingness to be interviewed about their experiences of side effects by 
completing the survey and returning their contact details. Those who reported a 
suspected side effect experience within the previous six months were selected. All 
potential participants were contacted by phone/email and arrangements were 
made to interview them at a time and location suitable for them. Vouchers with a 
monetary value of £10 were offered to interviewees as an incentive to participate. 
Recruitment for interviewees was limited to the [Anonymised for review] area 
and suitable locations were agreed between researcher and interviewees. A list of 
topic areas and a topic guide was developed which was informed by previous 
research and the survey data.
17,20 
 Participants were asked to describe how they 
identified and coped with their side effects and its impact on their daily life. 
Interviewees provided written and verbal consent before the semi-structured in-
depth interviewing began. Interviews were audio-recorded using an Olympus 
Digital Voice Recorder WS-852 and transcribed verbatim using an Olympus AS-
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4000 Transcription Kit. The interview data were then entered into the data 
management programme NVivo (QSR NVivo 10) to facilitate analysis.  
Analysis 
The interview transcripts were analysed by the first author using thematic 
analysis.
21
  Thematic analysis was chosen as the most appropriate method as it is a 
flexible research tool that can identify, analyse and organise patterns/themes in the 
data. The six stages of analysis proposed by Braun and Clarke were followed - 
familiarisation with transcripts; identification of initial codes which were 
developed into themes; reviewing these themes and creating thematic maps to 
identify relationships between themes and sub-themes; further review and refining 
to establish the key themes. A line-by-line analysis of the transcripts was 
conducted which involved repeated readings of the transcripts and making initial 
notes (BO’D). Transcripts were checked by supervisor (JK) and coding was 
discussed with an expert mentor with extensive phenomenological research 
experience in health research (AK). The emergent themes were identified, 
reviewed and refined to create a thematic map (BO’D; AK).  Saturation in coding 
continued until no other emergent themes were being generated at which point 
recruitment of potential participants for interview was discontinued. Analysis of 
the interviews led to the creation of main themes and sub-themes which are 
presented in the Results section. The main themes that were identified are 
supported with appropriate quotations from the interview transcripts. These 
distinctive/poignant quotations were selected in line with common research 
practice and were identified as the most representative of the research findings.
3,22
    
Results 
The final sample was composed of 10 females and 5 males. Their ages ranged 
from 25 to 80 years. A response rate for interviews of 9.6% was achieved – 22 
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potential participants from 230 returned surveys. One participant supplied an 
incorrect email address and could not be contacted. The remaining 21 were 
contacted by telephone/email at their preferred times. In total 19 confirmed their 
agreement to be interviewed; participants were contacted by telephone and 
arrangements for interview dates, times and locations were made. Fifteen 
participants were interviewed, by which time saturation in coding was reached 
and the interviews ceased. The remaining four individuals were contacted, 
thanked for their participation and advised they would not be interviewed. A 
demographic summary for each participant, including medical conditions and 
causative drugs is shown in Table 1.  
[<<<Table 1 here>>>] 
Analysis identified six main themes: side effect experience, identification, 
adherence, information use, coping and body awareness. These six main themes 
and sub-themes are presented in Figure 1. 
[<<<Figure 1 here>>>] 
 
Theme 1: Side effect experience 
All the participants related the multidimensional nature of their experience of side 
effects. They identified a range of physical symptoms which contributed to the 
somatic experience of side effects: 
P10:”the one that impacted me the most was the mini-pill reaction..my 
moods were everywhere..it was making me feel even more agitated and 
depressed and..just all around horrible”  
   
 Most participants described these less obvious psychological symptoms as 
significant in terms of impact on their lives:  
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P7: “I was really shocked that little tiny patch could do so much to your 
mental stability and the way that you felt..Yeah cos it was a total 
nightmare” 
 
Around half of participants also linked their SE experience to explicit economic 
effects for the individual. These included medication costs, costs of treating SE 
and work productivity. Participants also reported that attentional biases towards 
negative symptoms could facilitate maintenance/escalation of these symptoms: 
P12: “When I woke up and I was having the breathing issues and I saw 
just how swollen everything was ..and I heard my breathing I was very 
scared…I was panicking about it” 
  
Most interview participants indicated the significant impact which medication 
beliefs had on their side effects experience. These beliefs were extensive in their 
range and included their attitudes towards their medication, their confidence in 
their own ability to manage side effects, as well as their perceptions about their 
health status: 
P5: “when I first started taking it for the first fortnight I was getting up 
with headaches every morning..once or twice I had to take medication..but 
other then that it’s just get out and get some fresh air”      
          
                            
P6: “this wasn’t life-saving medication that I had to be on 
there..(pause)..there were options for me”    
 
The mediating effects of a positive doctor-patient relationship on negative 
medication beliefs were also described by the interviewees. A positive doctor-
patient relationship can intervene indirectly in the SE experience, by 
influencing/altering an individual’s negative medication beliefs. Participants 
indicated some of the characteristics of a positive relationship which centred on 
concepts of communication, engagement and accessibility: 
P2: “I think that he gave me the opportunity to say..I’m willing to take the 
risk take this medication because he gave me that opportunity I feel that..I 
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can trust him with other things as well even if there’s something down the 
road causes another reaction cos he’s very open about it you know” 
 
P8: “Best G.P. in the whole wide world accessible no problem if you need 
to see him or one of his chums that day”  
 
Theme 2: Identification 
Participants described the different processes they used to identify their side 
effect. These constructed cognitive processes included eliminatory thinking, 
cognitive linking of medicines to symptoms and acquisition of knowledge: 
P1: “It was new so I had been using my other four medicines and they 
didn’t give me a problem..so I think that’s one of the things that occur to 
me....This is a new medication” 
 
All participants used the timing of the symptoms to make the causal link between 
the medicine and the suspect adverse drug reaction. The timing of symptoms 
onset varied but the sequence of medicine leading to symptoms was common 
across participants:  
P13: “I said to my doctor I took a couple of para..of co-codamol and then 
about five or ten minutes later my face started coming up like this”  
  
Interview participants used varied information sources - both formal and informal 
- to find out about their side effects. These included HCPs, patient information 
leaflets (PILs) or the Internet to find out about their side effects. Past experiences 
of side effects also influenced participants’ use of PILs. Participants were more 
likely to read PILs if their medicines were to be taken regularly or for a prolonged 
period of time:  
P6: “unless it was something like an antibiotic that I’d been prescribed for 
infection or something and then I wouldn’t necessarily bother but 
something that you’re taking regularly over a long period of time then 
yeah I would look at the information leaflet yeah”   
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Theme 3 Adherence 
This study found that the medication beliefs of participants had a role in their 
decisions about adherence. These beliefs ranged from self-perceptions about their 
abilities to manage the SE, to considering whether the benefits of controlling a 
chronic condition outweighed the burden of SE and general beliefs that over 
prescribing by HCPs is a current issue:  
P15: “a side effect is just usually I call it just a mild annoyance..it’s 
nothing that usually bothers me much usually it’s like silly little 
headaches”  
 
Theme 4 Information use 
All the participants used varied information sources - formal and informal - to 
find out about side effects. These included HCPs, the Internet and family/friends. 
PIL use by participants was influenced by their past experiences of side effects: 
P10: “after what happened with the tetracycline I always read them now 
because I want to be prepared in case something did happen like that 
again”       
 
Participants also described the role of the Internet in the self-management of side 
effects. All participants considered that the Internet should be used with caution 
when seeking information on SE. However specific sites – such as NHS Choices47 
- were identified as being trustworthy. In addition on-line patient forums were 
specifically identified as useful in offering personal narratives of medical 
experiences: 
P3: “I got in touch with the association that was linked to my particular 
issue you know got on to their website and they were brilliant..basically 
my life savers”  
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However participants also described the tendency to over attend to negative 
information on the Internet: 
P11: “If I wanted to know anything about the tablets I would Google. 
Usually if I do that I come off and phone the local funeral directors 
because you always see the bad part of it”     
 
Theme 5 Coping  
Interview participants described the coping strategies they used to manage their 
side effects.  They used a variety of strategies which included information 
seeking, social support seeking and non-adherent behaviours. The majority 
engaged in information seeking activities, particularly in accessing specialised 
sources of information: 
P4: “I did go and see the pharmacist down here (pause) he said to me get 
to your GP I think you’re having a reaction to something you’ve taken” 
 
Around a quarter of participants also described negative coping strategies which 
involved cognitive factors such as negative expectations and excessive 
rumination. Participants also identified the influential role that symptom 
interpretation can have on coping behaviours. Focus on symptoms could result in 
escalation of these symptoms and result in coping behaviours such as sleeping 
more or pre-planning social outings: 
P7: “I know that I’ve got at least 10 minutes to find the loo..I look around 
for loos and stuff like that and I know where they are and then I can run to 
them if I need to”   
 
Most participants articulated the disparity which can exist between information 
about side effects risks versus patient understanding and perceptions of side 
effects risk:  
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P14: “when they gave you the medication they sort of say you may have 
side effects but it wasn’t explained in a way that you felt you understood or 
how it should be. It was kind of generalisations”  
 
Theme 6 Body awareness 
The final theme was linked to body awareness. Many participants indicated that 
attending to body signals was an essential element of their positive self-care 
health behaviours: 
P9: “..cos over the years I’ve learned how my body is, how it works, how 
it feels and..I’m not a hypochondriac or anything like that. But I know”    
          
            
P2: “I’m very aware of what my body does because the illnesses I’ve had 
most of my life..so..I don’t play about I know when something is right and 
wrong”  
 
Discussion         
This study contributes to research that examines side effects – its goal as a 
qualitative study is not to generalise but to provide a clearer understanding of 
individuals’ experiences of side effects.  It provided information on the strategies 
employed by patients to manage SE. These strategies varied greatly and included 
both cognitive and behavioural responses such as non-adherence; HCP 
consultation; seeking information from a range of sources and seeking social 
support. Decisions were made by patients about adherence to their medicines 
when they experienced side effects.  A range of factors influenced these decisions 
including established health beliefs; previous SE experiences; cognitive biases; 
perceived severity of SE; individuals’ coping styles and HCP interactions.   
SE experience: physical, psychological and economic effects 
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The interviewees described a wide range of physical and psychological symptoms 
which had both explicit and implicit impact on their lives. The explicit impact was 
primarily related to physical symptomology such as stiffness, headaches or rashes. 
Participants described the implicit impact of side effects as significant and linked 
to psychological symptoms. This pattern of symptomatology is supported by 
previous research into patient reports of side effects, which found that these  
generally provide a detailed extensive picture of ADRs and their impact.
23,24
  In 
patient reports physical effects are generally the most frequently reported ADRs, 
with patients reporting more ADRs than HCPs.
25,26,27,28
  Patients can have 
differing levels of susceptibility to psychological effects.
29
 Previous research 
supports the finding regarding the impact of psychological effects with patients 
describing changes in mood, memory and/or behaviour as distressing and 
persistent in nature.
15,30
 Participants also linked their SE experience to explicit 
economic effects for the individual. These included medication costs, costs of 
treating SE and work productivity. This supports previous research into side 
effects which has also found general economic effects with significant costs to 
healthcare services and loss of productivity.
3,24
  
SE experience: attentional biases to negative symptoms 
Participants reported that attentional biases towards their negative symptoms 
could facilitate maintenance/escalation of these symptoms. Research has found 
that excessive patterns of attention to negative stimuli play a central role in 
anxiety and depression disorders.
31,32
 Attentional biases can negatively impact on 
the subjective appraisal and perception of symptoms in gastrointestinal 
disorders.
33,34
 This can lead in turn to symptom escalation/persistence and 
avoidant health behaviours. Attention resources are allocated to symptom-related 
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stimuli over neutral stimuli. This in turn can lead to impaired cognitive processing 
of the symptom cues, as experienced by the interview participants.  
SE experience: medication beliefs 
Interview participants indicated the significant impact which medication beliefs 
had on their side effects experience. These beliefs were extensive and included 
their attitudes towards their medication, their confidence in their own ability to 
manage side effects, as well as their perceptions about their health status. 
Research has explored the impact that patients’ perceptions and medication beliefs 
have on their health behaviours. Studies have found that negative medication 
beliefs can be a factor for non-adherent and information seeking behaviours.
26,35
  
The mediating effects of a positive doctor-patient relationship on negative 
medication beliefs were also mentioned by the interviewees. A patient’s negative 
medication beliefs could be altered by their interaction with an engaged, 
accessible HCP with good communication skills. 
Identification: constructed cognitive processes 
A system of identifying SE based on constructed cognitive processes, was 
common across participants. These results are supported by research which has 
identified processes where symptoms are filtered and allocated significance 
through patients’ cognitive systems.35,36,37  Participants also used timing of the 
symptoms to link SE to their medicine. Previous studies support these findings 
and established that patients use temporal associations to assess suspected side 
effects
7,33,34 
a key criteria in professional causality assessments. Also, common 
across interview participants was the use of aids such as PILs and HCPs to 
confirm the side effect. This too mirrors previous research which found that the 
majority of patients used HCPs, patient information leaflets (PILs) or the Internet 
to find out about their side effects. 
19,39
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Adherence: medication beliefs 
The medication beliefs of participants had a role in their decisions about 
adherence. These beliefs ranged from self-perceptions on their abilities to manage 
the SE, to considering whether the benefits of controlling a chronic condition 
outweighed the burden of SE. Previous research investigating medication beliefs 
and non-adherence have shown mixed findings. Associations between medication 
beliefs and non-adherence have been found in a variety of patients – with 
cardiovascular conditions, HIV and epilepsy.
40,41,42
  However other studies 
involving patients with cardiovascular conditions and asthma found medication 
beliefs were not related to adherence.
43,44
 Recent research has found that patients 
with negative medication beliefs could misattribute symptoms to a medication and 
consequently decide to stop taking their medication.
26,44,46
  
Information use: formal and informal 
Participants used varied information sources to find out about their side effects. 
This mirrors previous research which found that the majority of patients used 
HCPs, PILs or the Internet to find out about their SE.
18,39
 All participants 
considered that the Internet should be used with caution but identified on-line 
patient forums as useful in offering personal narratives of medical experiences. 
Research has shown that such interactive sites can influence patient health 
behaviours.
48,49
 Participants also described the tendency to over attend to negative 
information on the Internet. These attentional biases to negative stimuli have been 
identified as potential barriers to effective use of online resources.
50,51,52
 
Coping: strategies  
The interviewees had a variety of coping strategies which included information 
seeking, social support seeking and non-adherent behaviours. Previous research 
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supports this pattern of coping, with social support seeking being the most 
common strategy, followed by information seeking.
26,53
 Most of the interviewees 
engaged in information seeking behaviours. Research has also found that the 
process of obtaining information may be influenced by an individual’s coping 
style.
54,55
  The levels of information that patients require varies greatly from those 
who require detailed medical information to those whose preference is to reduce 
discomfort by avoiding detail. Many of the participants used negative coping 
strategies such as negative expectations and excessive rumination. Research has 
shown that affective cognitions can have significant impact on health outcomes.
56 
 
Cognitive and emotional processes can have a significant role in health-protective 
and health-risk behaviours.
54,57,58,59
 
Coping: disparity between physician and patient beliefs 
Participants identified the disparity which can exist between physician beliefs 
about side effects versus patient beliefs about side effects. A previous review 
found that patients had reservations about the overall quality of PILs and changes 
could be made to improve patients’ understanding of PILs.60  In addition to 
confusion about side effects risk some participants described dismissive responses 
from their HCPs when they discussed their SE. Research studies provide 
supporting evidence for such dismissive attitudes amongst some HCPs. This 
disparity between HCPs and patients’ perspectives on SE can lead to decreased 
SE reporting from patients.
61,62,63,64,65,66
 
Body Awareness: positive self-care  
The final theme was linked to body awareness. Interview participants indicated 
that attending to body signals was an essential element of positive self-care health 
behaviours. Research has defined body awareness as an active process which 
involves an awareness of and attentional focus on body cues and signals.
67
 Body 
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awareness has been identified as a complicated construct which can be key to both 
adaptive and non-adaptive health behaviours. Adaptive body awareness/sensitivity 
has been identified as occurring in combination with non-judgemental attention to 
the immediate sensations/effects.
67
  Recent research has found that patients who 
ignored their bodily signals displayed lower levels of physical and psychological 
health.
68
 Hypochondriac tendency was reduced in those with high sensitivity to 
body symptoms that was combined with a non-catastrophising mode of 
attention.
69
 To date research has not specifically identified body awareness as a 
factor in identifying side effects. However this study found that body awareness 
and an appreciation of how the body reacts in differing circumstances is important 
in the context of SE from medicines. This suggests that SE could be mediated by 
adopting a self-focus that directs attention to the effects in a mindful, non-
judgmental manner. Further research is required to explore the role of body 
awareness in SE and potential self-management techniques to manage SE. 
Common Sense Model of self-regulation (CSM) 
Thematic analysis of the interview transcripts revealed a number of relevant and 
prominent themes. These emergent themes correspond with an established model 
of illness behaviour – Levanthal’s Self-Regulation model /Common Sense Model 
of self regulation (CSM).
70
 Leventhal’s Self-Regulatory Model (1987) was 
initially composed of three main cognitive constructs:
71
 
• Representations – representations of the health-related threat which 
interprets the experience through cognitive representations such as symptoms, 
social cues, consequences 
• Coping strategies – action planning such as avoidance, information 
seeking, seeking medical attention 
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• Appraisal - where the success or failure of coping strategies are assessed. 
Over the years research has found that patients process information about physical 
symptoms according to their prototypical perceptions about associations between 
diseases and particular symptoms. Patients use their previous personal health 
experiences or knowledge of the experiences of others to identify symptoms and 
use preconceived perceptions about side effects to assist them in labelling and 
interpreting symptoms linked to the consequences of treatment.
72,73
  Levanthal’s 
model has developed into the CSM, identifying a prototype/cognitive schema 
used by patients to evaluate and assist them in identifying these symptoms as side 
effects. This specific ADR prototype is composed of five elements/cognitive 
domains. The five elements are described as identity (symptoms/label); cause; 
timeline; consequences and cure.
73
  Within the CSM factors such as prior 
experiences with side effects and symptom amplification can lead to 
misinterpretation of symptoms as side effects of medications. The CSM stresses 
the central role that symptom interpretation plays in an individual’s health 
outcomes such as self-management and care seeking.
74
 The explanatory power of 
CSM has been improved by the addition of medication beliefs to the model, which 
could influence patients’ non adherence behaviours when they experience SE.75 In 
the past this theory has been used as a framework for research in managing 
chronic illnesses such as psoriasis, rheumatoid arthritis and multiple 
sclerosis.
76,77,78
 However researchers have also suggested that the CSM could be 
used to assess side effects from medicines.
53
 This study suggests that a dynamic 
model such as the CSM could be an effective theoretical framework to investigate 
how patients identify and manage their side effects.
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Limitations of the study 
 The main purpose of this study was to form a rich picture of individuals’ 
experiences of side effects. This was achieved through face-to-face interviews 
however self-selection bias may apply to these interviewees as they signalled their 
desire to participate from a larger survey sample. It is possible that they were 
particularly interested in SE as they had experienced significant effects which 
they regarded as being outside of the common SE experience. However the 
interviewees had differing ages, education, medical conditions and number of 
medicines used, which suggests that participants may be likely to have a wide 
range of opinions and experiences. The use of incentives – vouchers – may have 
led to bias in recruitment however the vouchers were of small monetary value 
which reduced their significance. A limitation of this study was related to the 
inconsistency which can surround theoretical saturation.  Saturation in coding was 
reached after 15 interviews however qualitative studies have reported saturation 
after just 6 interviews.
79
 In this study independent investigators were used to 
increase the overall reliability of the analysis.  
 
Implications for research  
The findings of this study indicate that further research may be warranted in 
several areas. These include the impact of medication beliefs and body awareness 
on the SE experience, as well as the challenges involved in effective 
communication of SE risk. The medication beliefs of interview participants were 
wide ranging and had a role in their decisions about adherence. Current measures 
of medication beliefs may not fully capture the wide range of factors inherent in 
patients’ medication beliefs. Another focus for continued investigation is the role 
of body awareness in the context of SE. It is possible that SE could be mediated 
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by adopting a self-focus that directs attention to SE in a mindful, non-judgmental 
manner. Mindfulness training in patients who are most likely to experience SE 
could be beneficial, however more research is required to determine if 
mindfulness techniques could assist these patients.  This study also suggests that 
disparities can arise between information about side effects risks and patients’ 
interpretation of these risks. Comprehensive information for medicine users needs 
to avoid ambiguity while clearly imparting the risks and potential impact of SE 
from medicines. Communication training for HCPs which focuses on providing 
such tailored information could improve outcomes for patient-centred healthcare. 
 
Conclusions 
This study highlights the complexity in individuals’ experiences of SE and the 
wide variety of information sources used by patients to confirm SE. It also 
provided information on the impact of SE on day-to-day life and patients’ 
attitudes towards medicines and HCPs. Further research is required to establish 
how best information on SE can be tailored to patients’ needs in a clear, 
consistent, reliable and useful form and how patients can be assisted to identify 
SE and engage in meaningful discussions with HCPs about their experiences. 
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Table 1: Demographic summary and characteristics of participants 
 Gender Age Employment Education Medical condition No. of meds Causative med 
P1 Female 41-50 FT F ed Underactive thyroid 5-8 Carbimazole 
P2   Female 41-50 FT Univ COPD; Lupus; MS 5-8 Hydroxychloroquine 
P3 Female 51-60 Disability SL 16 RA 2-4 Clarithromycin 
P4 Male 41-50 FT F ed Cardiac disease 2-4 Lisinopril 
P5 Male 61-70 Retired Fed Hypertension 5-8 Simvastatin 
P6 Female 51-60 FT Univ Menopause 1 HRT 
P7 Male 61-70 Retired SL 16 Chronic pain 2-4 Morphine patches 
P8 Male 61-70 Retired F ed Arrhythmia 5-8 Amiodarone 
P9 Male 61-70 FT SL 16 Depression 2-4 Mirtazapine 
P10 Female Below 40 FT Univ Acne 2-4 Tetracycline 
P11 Female 71-80 Retired SL 17/18 Dental infection 2-4 Antibiotic 
P12   Female 71-80 Retired Univ Reflux 2-4 Lansoprazole 
P13 Female 61-70 Retired Univ Spondylosis 2-4 Co-codamol 
P14 Female 61-70 Retired SL 17/18 Asthma 1 Prednisolone 
P15 Female 51-60 Disability Univ FS More than 8 Multiple medicines 
P = Participants; FT = Full time;; F ed = Further education; SL=School leaver; Univ = University 
COPD= Chronic obstructive pulmonary disease; FS=Fibromyalgia syndrome;HRT= Hormone replacement therapy; MS= Multiple sclerosis; RA=Rheumatoid 
arthritis 
10:32:42 interview hrs recorded; 20.26-127.02 minutes (M = 42.16; SD ± 29.15). 
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 Fig 1: Six main themes and subthemes identified in thematic analysis 
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